These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 33730337)

  • 21. Addition of Basal Insulin to Oral Antidiabetic Agents in Patients with Inadequately Controlled Type 2 Diabetes Leads to Improved HbA1c Levels: Metabolic Control, Frequency of Hypoglycemia, and Insulin Titration Analysis as Results of a Prospective Observational Study (BALI Study).
    Brož J; Janíčková Ždárská D; Štěpánová R; Kvapil M
    Diabetes Ther; 2019 Apr; 10(2):663-672. PubMed ID: 30788806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors.
    Gómez-Peralta F; Abreu C; Mora-Navarro G; López-Morandeira P; Pérez-Gutierrez E; Cordero-García B; Brito-Sanfiel M
    Exp Clin Endocrinol Diabetes; 2018 May; 126(5):268-276. PubMed ID: 28704854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of diabetic ketoacidosis, severe hypoglycemia and glycemic control among children and young adults with type 1 diabetes mellitus treated with premixed versus basal-bolus insulin therapy.
    Chou WY; Li YR; Chan WK; Chen ST
    Biomed J; 2018 Dec; 41(6):348-355. PubMed ID: 30709576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Where to Initiate Basal Insulin Therapy: Inpatient or Outpatient Department? Real-World Observation in China.
    Chen M; Zhang P; Zhao Y; Duolikun N; Ji L
    Diabetes Metab Syndr Obes; 2022; 15():3375-3385. PubMed ID: 36341227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diabetes-related outcomes with basal-bolus vs. premixed insulin among veterans with type 2 diabetes: A single institutional retrospective study.
    Bai R; Batra K; Yap C; Izuora K
    Am J Med Sci; 2023 Jul; 366(1):38-43. PubMed ID: 37040827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
    Davies M; Evans R; Storms F; Gomis R; Khunti K
    Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
    Vos RC; van Avendonk MJ; Jansen H; Goudswaard AN; van den Donk M; Gorter K; Kerssen A; Rutten GE
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006992. PubMed ID: 27640062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EADSG Guidelines: Insulin Therapy in Diabetes.
    Silver B; Ramaiya K; Andrew SB; Fredrick O; Bajaj S; Kalra S; Charlotte BM; Claudine K; Makhoba A
    Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA.
    Blonde L; Meneghini L; Peng XV; Boss A; Rhee K; Shaunik A; Kumar S; Balodi S; Brulle-Wohlhueter C; McCrimmon RJ
    Diabetes Ther; 2018 Jun; 9(3):1347-1358. PubMed ID: 29600507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes.
    Nicolucci A; Ceriello A; Di Bartolo P; Corcos A; Orsini Federici M
    Diabetes Ther; 2020 Mar; 11(3):573-584. PubMed ID: 31873857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
    Owens DR; Bolli GB; Charbonnel B; Haak T; Landgraf W; Porcellati F; Traylor L; Kautzky-Willer A
    Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
    Valensi P; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y;
    Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study.
    Temelkova N; Vladeva S; Delchev A; Ivanova K; Gerasimova-Zheleva Y; Kuneva T; Pehlivanova V; Popivanov P
    Diabetes Ther; 2019 Jun; 10(3):981-993. PubMed ID: 30919317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GOAL study: clinical and non-clinical predictive factors for achieving glycemic control in people with type 2 diabetes in real clinical practice.
    Al Mansari A; Obeid Y; Islam N; Fariduddin M; Hassoun A; Djaballah K; Malek M; Dicker D; Chaudhury T
    BMJ Open Diabetes Res Care; 2018; 6(1):e000519. PubMed ID: 30023075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Human Premixed and Basal Plus Short-Acting Insulin Regimens for Individuals With Type 2 Diabetes During Ramadan Fasting.
    Altemimi MT; Odhaib SA; Imran HJ; Alhamza A; Almomin A; Mansour AA
    Cureus; 2020 Dec; 12(12):e11976. PubMed ID: 33425548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Wang C; Mamza J; Idris I
    Diabet Med; 2015 May; 32(5):585-94. PubMed ID: 25594251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
    Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
    Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors that affect the Glycemic Control Achieved by Switching to Insulin Degludec/ Aspart in Insulin-Treated Patients with Type 1 and Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study.
    Onder CE; Kuşkonmaz SM; Koc G; Firat S; Omma T; Taskaldiran I; Gokbulut P; Culha C
    Acta Endocrinol (Buchar); 2020; 16(4):443-448. PubMed ID: 34084235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of 50/50 Premixed Insulin Analogs in Type 2 Diabetes: Systematic Review and Clinical Recommendations.
    Deed G; Kilov G; Dunning T; Cutfield R; Overland J; Wu T
    Diabetes Ther; 2017 Dec; 8(6):1265-1296. PubMed ID: 29116584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.